Skip to main content
OpenTrials
Completed

NCT Number: NCT04087278

Cardiovascular Health Arterial Stiffness Raspberry and Microbiome (CHARM)

In this study, the investigators aim to determine the health benefits of red raspberry ellagitannin consumption on cardiovascular health. The study population is stratified according to the urolithin metabotypes (gut-microbial metabolic profile): UM-0, UM-A and UM-B.

The investigators will evaluate changes in blood pressure, endothelial function, arterial stiffness, lipid profile, cognitive performance and gut microbiome composition.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London

London, SE1 9NH, United Kingdom

About this study

Red raspberries are a good source of polyphenols including ellagitannins. Previous work suggests that urolithins, gut microbial metabolites derived from ellagitannins contained in raspberries, can improve vascular health. It has also been observed that the capacity of the gut microbiome to metabolize urolithins can influence the cardiometabolic response to ellagitannin consumption. In this work the investigators aim to investigate whether urolithin metabotypes (UM-A, B and 0) can influence the vascular response to a (poly)phenol-rich breakfast containing red raspberry ellagitannins in a healthy UK population.

You will be stratified by metabotype in a first phase (NCT03573414) and are then randomly allocated to treatment or placebo. Outcomes are measured at baseline and after 12 weeks consumption of the study product.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy men or women aged 20-70 years old
  • BMI between 18.5-35 kg/m²
  • Normotensive: SBP lower than 140 mmHg or DBP lower than 90 mmHg
  • Willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body weight over the duration of the study
  • Able to understand the nature of the study
  • Able to give signed written informed consent

Exclusion criteria

  • Have required treatment for hypertension at any time (e.g. statins, aspirin, blood pressure lowering drugs)
  • BMI outside range
  • Manifest cardiovascular disease including coronary artery disease, cerebrovascular disease and peripheral artery disease
  • Currently treated with a diet
  • Chronic-acute disease
  • Unstable psychological condition
  • Diabetes mellitus, metabolic syndrome, acute inflammation, terminal renal failure, malignancies or abnormal heart rhythm (lower or higher than 60-100 bpm)
  • History of cancer, myocardial infarction, cerebrovascular incident or kidney abnormality
  • Allergies to berries, flax seeds and soy milk or other significant food allergy
  • Requiring chronic antimicrobial or antiviral treatment
  • Reported having taken food supplements, dietary supplement or herbal remedies within 1 month of study start
  • Weight loss of more than 10% body weight in the previous 6 months
  • Reported participant in another study within one month before the study start
  • Smoke an irregular amount of cigarettes per day or planning to quit smoking in the next 3 months
  • Unable to tolerate breakfast ingestion
  • Pregnant woman/ lactating woman/ woman planning to become pregnant/ premenopausal women who do not have a regular menstrual cycle/ premenopausal women who do not have adequate method of contraception
  • Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements
  • Unable to swallow the capsule.

Treatment and study plan

Red Raspberry Ellagitannin Extract

Dietary Supplement

Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)

Matching Placebo

Dietary Supplement

Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)

Primary outcomes

  1. Change in flow-mediated dilation (FMD)

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on flow-mediated dilation at 12 weeks post consumption

Secondary outcomes

  1. Change in office blood pressure

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on office systolic and diastolic blood pressure, at 12 weeks post consumption

  2. Change in heart rate

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on heart rate, at 12 weeks post consumption

  3. Change in blood flow velocity

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on blood flow velocity at 12 weeks post consumption

  4. Change in pulse wave velocity (PWV)

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on pulse wave velocity (PWV) using a Sphygmocor device, at 12 weeks post consumption

  5. Change in augmentation Index (AIx)

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on augmentation Index (AIx) using a Sphygmocor device, at 12 weeks post consumption

  6. Change in blood lipid concentrations

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on blood lipids (Total, HDL and LDL cholesterol, triglycerides), at 12 weeks post consumption

  7. Change in blood inflammatory markers (circulating concentrations)

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on blood inflammatory markers (CRP, IL-6), at 12 weeks post consumption

  8. Change in 24-hour heart rate

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on 24-hour heart rate, using a monitor, at 12 weeks post consumption

  9. Change in 24-hour ambulatory blood pressure

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on 24-hour ambulatory blood pressure (SBP and DBP), using a monitor, at 12 weeks post consumption

  10. Change in 24-hour AIx and PWV

    Time frame: Baseline vs 12 weeks post-consumption

    Determine the effect of the Red raspberry ellagitannin extract vs Placebo on 24-hour arterial stiffness (AIx and PWV), using a monitor, at 12 weeks post consumption

Other outcomes

  1. Change in urinary metabolic (poly)phenol metabolite concentrations

    Time frame: Baseline vs 12 weeks post-consumption

    Measured by liquid chromotography-mass spectrometry (LC/MS) at baseline and after 12 weeks in a 24h urine sample

  2. Change in plasmatic metabolic (poly)phenol metabolite concentrations

    Time frame: Baseline vs 12 weeks post-consumption

    Measured by liquid chromotography-mass spectrometry (LC/MS) at baseline and after 12 weeks

  3. Gut microbiome composition

    Time frame: Baseline vs 12 weeks post-consumption

    Analysis of the microbiome composition and diversity at baseline and after 12 weeks post-consumption

  4. Change in verbal-episodic memory performance assessed by AVLT

    Time frame: Baseline vs 12 weeks post-consumption

    Assessment of the performance with the difference of words remembered between baseline and after 12 weeks post-consumption.

  5. Change in executive function performance assessed by the switching task

    Time frame: Baseline vs 12 weeks post-consumption

    Assessment of the performance calculating the difference in mistakes (not applying the right rule when needed) between baseline and after 12 weeks post-consumption.

  6. Change in visual-spatial working memory performance assessed by the Corsi task

    Time frame: Baseline vs 12 weeks post-consumption

    Assessment of the performance with the difference in mistakes remembering the block patterns between baseline and after 12 weeks post-consumption.

  7. Change in mood using the PANAS questionnaire

    Time frame: Baseline vs 12 weeks post-consumption

    Assessment of the change in the mood using the PANAS questionnaire containing 10 positive affects and 10 negative affects rated using a 5-point likert scale that ranges from "(1) Not at all to (5) Extremely", between baseline and after 12 weeks post-consumption.

Sponsors and collaborators

Lead sponsor

King's College London

Other

Collaborators

  • Centro de Edafología y Biología Aplicada del Segura
  • Washington Red Raspberry Commission

Registry information

Acronym: CHARM

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Sep 12, 2019
Registry last updated
Nov 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.